Apixaban is indicated for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age ≥75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥II) including patients unsuitable for warfarin. Compared to warfarin, Apixaban also results in less bleeding, including intracranial hemorrhage. Apixaban is also indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE). It is also used for the prevention of recurrent DVT and PE in adults.
Apixaban is also indicated in the prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery.
Other Services
Country
Support
Account
Sign Out